Squarepoint’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Squarepoint’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,190	Closed	-$35K	–	1638
2015 Q4	$35K	Buy	+1,190	New	+$36K	﹤0.01%	1199
2015 Q2	–	Sell	-3,020	Closed	-$323K	–	686
2015 Q1	$323K	Buy	+3,020	New	+$288K	0.11%	277

Other funds holding PTX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Squarepoint's PTX Position: Q1 2016 in Review

Squarepoint sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2016, closing a stake of 1,190 shares — an estimated $35K sold.

Squarepoint first reported a position in PTX in Q1 2015 and held it in 2 quarters. The position peaked at $323K in Q1 2015. 88 funds tracked by Wall St. Rank hold PTX as of Q1 2016.

Squarepoint reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2016 after selling out during the quarter.
Squarepoint sold 1,190 Pernix Therapeutics Holdings, Inc. shares in Q1 2016, an estimated $35K.
Squarepoint first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2015 and held it in 2 quarters.
Squarepoint's Pernix Therapeutics Holdings, Inc. position peaked at $323K in Q1 2015.
88 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2016.

Based on Squarepoint's 13F filing for Q1 2016, filed 16 May 2016.